Source: Pharmacy Times articles
Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.
Recent Content
- Value of Spectral CT Techniques for the Assessment of Bone Marrow Infiltration in Multiple Myeloma: A Systematic Literature Review
- EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma
- VIDEO: Four drugs ‘appear to be better’ in treatment of newly diagnosed multiple myeloma
- VIDEO: Cilta-cel may offer ‘cure’ in relapsed, refractory multiple myeloma
- Treatment-related cognitive changes in multiple myeloma: A systematic review and meta-analysis
- NCCN Flash Update: Linvoseltamab Added as Preferred Regimen After 4 Prior Therapies for Multiple Myeloma
- FDA Panel Rejects Belantamab Mafodotin Combinations for Multiple Myeloma, Citing Safety Concerns
- FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma
- Blenrep fails to receive ODAC support for multiple myeloma use
- Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma